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Abstract
Aim The aim of the study was to evaluate renal function and
to assess the usefulness of the following nephrotoxicity
markers: cystatin C (CYS C), beta-2 microglobulin (B2MG)
and neutrophil gelatinase-associated lipocalin (NGAL) in 38
(18 girls, 20 boys) children previously treated for central nervous
system malignancy.
Material Median age at evaluation was 13.7 years (range 2.1–
22 years). The mean follow-up time after the completion of
chemotherapy was 3.2 years (range 0.16–6.5 years).
Results Subclinical chronic kidney disease (estimated glomer-
ular filtration rate: eGFR 90–60ml/min/1.73 m2) was found in
22 patients (58%), while renal insufficiency (eGFR 30–60ml/
min/1.73 m2) was found in six children (16 %). It has been
demonstrated statistically significant negative correlation be-
tween the eGFR and cystatin C concentration (p < 0.0001) and
eGFR and beta-2 microglobulin concentration (p < 0.02).
Conversely, there was no correlation between eGFR and
NGAL. Thirteen children (34 %) developed drug-induced
tubulopathy: decreased tubular reabsorption of phosphate
(TRP) and renal tubular threshold for phosphate (Tmp/GFR).
Conclusion Children treated for CNS tumours often develop
drug-induced chronic renal disease, involving the glomeruli
and/or renal tubules. Cystatin C and beta-2 microglobulin
seemed to be good markers for chronic kidney damage in
these patients, which is probably not true for NGAL.
Keywords Brain tumours . Kidney injury . Cystatin C .
Beta-2microglobulin . Neutrophil gelatinase-associated
lipocalin
Introduction
Central nervous system (CNS) tumours are, after leukaemias,
the most frequent malignancy in children. The number of
children successfully treated for different malignancies has
been increasing in recent years. Current 5-year survival rates
of 73.3 % for childhood brain tumours suggest that the major-
ity of children diagnosed with brain tumours will become
long-term survivors [1]. Improved treatment outcomes can
be attributed to the aggressive, multidrug chemotherapy,
which is associated with drug-induced toxicity as one of the
main adverse effects. Investigators from the Childhood
Cancer Survivor Study (CCSS) reported that in 30 years after
the cancer diagnosis, 73.4 % of survivors suffer from at least
one chronic disease and they are eight times more likely to
develop severe or life-threatening chronic health conditions as
compared to their siblings [2]. The highest number of drug-
induced complications is found in children treated for CNS
tumours [2]. Specific late effects frequently observed in brain
tumour survivors include neurotoxicity, neuro-cognitive defi-
cits, endocrine disorders, obesity, secondary malignancy and
kidney injury [1, 3–5].
Nephrotoxicity constitutes approximately 30 %, and ac-
cording to some authors, up to 70 % of cancer treatment
complications [6]. Platinum derivatives and alkylating
agents , both known for thei r wel l -es tabl ished
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nephrotoxicity, are primary chemotherapeutics used in the
treatment of brain tumours [6, 7].
Nephrotoxicity of cisplatin and carboplatin is due to uptake
of these drugs by the renal tubule cells. They cause damage to
nuclear and mitochondrial DNA, activation of apoptosis and
mediators of inflammation. These mechanisms result in kidney
damage that can lead to acute kidney injury (AKI) and chronic
lesions: fibrosis and tubular damage presenting with hypomag-
nesemia, hypocalcemia and distal renal tubular acidosis [7].
Alkylating agents: ifosfamide (IFA) and cyclophosfamide
(CPA) act by alkylation of DNA. The side effect of IFA may
be Fanconi syndrome—global proximal tubulopathy of the
kidney that results in wasting of phosphate, calcium, uric acid
and bicarbonates, as well as hyperaminoaciduria and
glucosuria with a normal serum glucose level [8]. Adverse
drug reaction from CPA is haemorrhagic cystitis.
Early detection and prompt treatment of chemotherapy-
induced complications, including kidney injury, significantly
affect the quality of life of cancer survivors.
Serum creatinine assay is the most common marker of kid-
ney injury used in clinical practice. However, serum creatinine
level fluctuations are neither sensitive nor specific response to
slight changes of glomerular filtration rate (GFR). Hence, it is
vital to search for the newer and better parameters, which
correlate with the severity of kidney injury. In this regard,
neutrophil gelatinase-associated lipocalin (NGAL), cystatin
C (CYS C), beta-2 microglobulin (B2MG) and interleukin-
18 (Il-18) appear now the most promising parameters [9,
10]. In many studies, these markers have been shown to be
good indicators of AKI [11], but their role in the evaluation of
chronic renal failure is still under investigation.
The aim of the study was to evaluate renal function in chil-
dren previously treated for CNS malignancy and to assess the
usefulness of the following chronic nephrotoxicity markers:
CYS C, B2MG and NGAL in this patient population.
Material and methods
Study group
Data on 38 children (18 girls, 20 boys) previously treated for
CNS tumour were analysed. The median age at diagnosis of
CNS tumour was 9.75 years (range 0.92–17.7 years). Median
age at evaluation was 13.7 years (range 2.1–22 years). The
mean follow-up time after the completion of chemotherapy
was 3.2 years (range 0.16–6.5 years). All patients were treated
in the Department of Paediatric Oncology, Haematology and
Chemotherapy at the Medical University of Silesia in
Katowice between 2004 and 2013 and evaluated between
January and June 2013 (Table 1).
The brain tumour treatment was in line with the
Standardized and Modified Programme of Diagnosis and
Comprehensive Treatment of Central Nervous System
Tumours in Children (2007), recommended by the Polish
Paediatric Group for Infant Neuro-oncology. It involved mul-
tidrug chemotherapy and radiotherapy administered in line
with the histopathological diagnosis. Most children received
both platinum compounds and alkylating agents (Table 2).
Following protocols were applied in patients depending on
their age and the type of neoplasm:
Protocol I (vincristine, etoposide, carboplatin,
cyclophosphamide, ifosfamide, lomustin
and cisplatin)—in children with
medulloblastoma, PNET and
anaplastic ependymoma.
Table 1 Clinical characteristics of the patients
Age at diagnosis (years) 9.75 (0.92–17.75)
Age at the time of investigation (years) 13.7 (2.1–22.0)
Sex
Boys 20 (52 %)
Girls 18 (48 %)
Height (cm) 151.2 (95.5–190.5)
Height SDS −0.95 (−4.5-1.8)
Weight (kg) 46.3 (15–79)
BMI SDS 0.06 (−2.9–0.87)
SBP (mmHg) 100.56 (88–135)
DBP (mm/Hg) 57.95 (43–87)
Histopathological examination:
Medulloblastoma 19 (50 %)
Ependymoma anaplasticum 4 (10 %)
Astrocytoma anaplasticum 4 (10 %)
Oligodendroglioma anaplasticum 1 (3 %)
Oligoastrocytoma anaplasticum 2 (5 %)
Primitive neuroectodermaal tumour 1 (3 %)
Glioblastoma multiforme 2 (5 %)
Germinoma 4 (10 %)
Carcinoma plexus choroidei 1 (3 %)
Tumor location:
Posterior fossa 19 (50 %)
Hemispheric location 12 (31 %)
Middle line 6 (15 %)
Brain stem 1 (3 %)
Resection:
Total resection 12 (31 %)
Gross total resection 7 (18 %)
Partial resection 18 (47 %)
Biopsy 1 (3 %)
Radiotherapy spinal lumbar and sacral Yes 22 (57 %)
No 16 (42 %)
SDS standard deviation score, SBP systolic blood pressure,DBP diastolic
blood pressure, BMI body mass index
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Protocol II (etoposide, ifosfamide, adriamycin,
cisplatin, vincristin, lomustin and
temodal)—in children with high-
grade glioma.
Protocol III (cisplatin, etoposide, carboplatin
and vincristine)—in children under
3 years of age.
Protocol V (etoposide, vinblastine, bleomycin,
cisplatin and carboplatin)—in
children with germ cell tumour.
Majority of children according the Therapeutic Protocol
have received cisplatin as 1-h bolus infusions on five consec-
utive days (5 × 20 mg/m2) during initial therapy (before radio-
therapy) and as 1-h bolus infusion on 1 day (1 × 75 mg/m2) in
the course of maintenance therapy (after radiotherapy). No
one received long-term ciplatin infusions. Appropriate hydra-
tion during chemotherapy was conducted to reduce the inci-
dence of cisplatin-induced nephrotoxicity. Mannitol and not
furosemide was administered during hydration to decrease
cisplatin-induced nephrotoxicity.
None of the patients received intravenous radiographic
contrast; in all patients, gadolinium-based contrast agents
were applied during magnetic resonance imaging. One patient
during febrile neutropenia has received aminoglycoside (dur-
ing 7 days) because of respiratory tract infection, and one child
received sulfonamides because of Pneumocytis carini
infection.
All patients had normal renal function before chemothera-
pymeasured by a new Schwartz formula (mean eGFR 101ml/
min/1.73 m2).
Laboratory methods and analysis
All enrolled patients underwent diagnostic evaluation includ-
ing blood pressure measurement, blood sample collection for
serum creatinine and electrolyte level (serum magnesium,
phosphorus, calcium, sodium, potassium, glucose) and CYS
C, NGAL and B2MG assays. The 24-h urine collection was
performed in order to assess the loss of phosphorus, sodium,
magnesium and calcium ions (in mg/kg/24 h). Furthermore,
plasma and urine osmolality, the urine specific gravity, pH,
presence of glucose, protein and albumin were determined.
Microalbuminuria was defined as losing more than 15 μg of
albumines per minute during 24-h urine collection. All the
tests were performed according to standardized routine
methods in a hospital laboratory with the Olympus 800u ap-
paratus. Additionally, an abdominal ultrasound scan was per-
formed in each patient.
Glomerular function was evaluated by determining
serum creatinine and by estimating GFR with Schwartz
formula and updated CKD Schwartz Equation (new
Schwartz formula) [12].
The Schwartz formula was defined as eGFR in ml/min/
1.73 m2 = height of child [cm] × k/serum creatinine [mg/dl];
k- = 0.413.
The new Schwartz formula equation was defined as
39.2 × (height [m]/serum creatinine [mg/dl]) 0.516 × (1.8/
CYS C serum concentration [mg/L] 0.294 × (30/BUN [mg/
dl]) 0.169 × (1,099 males/1 female) × (height of child [m]/
1.4) 0.1888 [12, 13].
Nephrotoxicity was defined according to indicates of
National Kidney Foundation (http://www.kidney.org/
professionals/KDOQI/guideline-/ckd):
Mild decrease of eGFR (eGFR 90–60 ml/min/1.73 m2)-
stage 2 of chronic kidney damage (CKD)
Moderate decrease eGFR (eGFR 60–30 ml/min/
1.73 m2)-stage 3 of CKD
Severe reduction eGFR (eGFR 30–15 ml/min/1.73 m2)-
stage 4 of CKD
Kidney failure (eGFR < 15 ml/min/1.73 m2)-stage 5 of
CKD
Tubular function was estimated by calculating the ratio of
the tubular reabsorption of phosphate (TRP) and renal tubular
threshold for phosphate (Tmp/GFR). TRP was defined as:
TRP (%) = 1 − (urine phosphorus concentration/urine cre-
atinine concentration) × (serum creatinine concentration/
Table 2 Nephrotoxic




Nephrotoxic chemotherapy Pathomorphological evaluation Number
of patients
Ciplatin, carboplatin, IFA MBL-HRG, PNET, EA, 14
Ciplatin, carboplatin, CPA MBL-SRG 9
Ciplatin, CPA Children under 3 years of age 4
Ciplatin, IFA HGG 6
Ciplatin, carboplatin Germ cell tumor 4
Carboplatin Carcinoma plexus choroidei 1
MBL-HRG medulloblastoma high risk group, PNET primitive neuroectodermal tumor, EA ependymoma
anaplasticum, MBL-SRG medulloblastoma slow risk group, HGG high-grade glioma
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serum phosphorus concentration) × 100. TRP dysfunction
was defined as TRP < 85 %.
Tmp/GFR—a quotient of maximal rate of tubular phos-
phate reabsorption and the glomerular filtration rate.
References ranges for children aged 2–15 years were 1.15–
2.6 mmol/l (21–47 mg/dl) according to http://www.baspath.
co.uk/test_directory/tindex/TmPGFR.htm [14].
Simultaneously, the serum levels of CYS C, B2MG and
NGAL were measured.
The level of B2MGwas assessedwith the immunoenzymatic
method and using commercial sets of B2-Mikroglobulin Elisa
Kit by Immundiagnostik AG, Germany. The detection limit was
defined as Bo + 2 SD and set to 0.1 mg/l.
CYS C was assayed by a commercial kit: Human Cystatin
C ELISA by BioVendor, Czech. The limit of detection is cal-
culated from the real CYS C values in wells and is 0.25 ng/ml.
The l e ve l o f NGAL was a s s e s s e d w i t h t h e
immunoenzymatic method and using commercial sets of
Human lipocalin-2/ngal ELISA by BioVendor, Czech. The
limit of detection is calculated from the real NGAL values in
wells and is 0.02 ng/ml.
The results of nephrotoxic markers were correlated with
clinical data: age at diagnosis, a type and total doses of che-
motherapy and time lapse from treatment completion.
The study was approved by the Ethical Committee of
Medical University of Silesia in Katowice. The written in-
formed consent was obtained from the parents of the
participants.
Statistical analysis
Most variables showed normal distribution (p > 0.05 in KS test)
and were characterized as mean values (min–max value).
Hypotheses were verified using the parametric Student t tests
for independent and dependent variables, respectively. The con-
tinuous data was analysed usingMann–WhitneyU or Kruskall–
Wallis test. The Spearman correlation coefficient was used for
correlation estimates. P value below 0.05 was considered statis-
tically significant. All statistical analyses were performed using
the STATISTICA data analysis software system version 11
(StatSoft, Inc. 2014 www.statsoft.com).
Results
The mean GFR estimated using Schwartz formula in the
whole group was 76 ml/min/1.73 m2, while GFR estimated
using revised Schwartz formula was 63 ml/min/1.73 m2.
There was a statistically significant difference between GFR
determined using the Schwartz formula and the revised
Schwartz formula equations (p < 0.0001).
Subclinical stage 2 of CKD (eGFR 90–60 ml/min/1.73 m2)
was found in 22 patients (58 %), and stage 3 of CKD (eGFR
30–60 ml/min/1.73 m2) was found in six children (16 %). The
results of investigations are shown in Table 3.
No significant correlation between patient age at diagnosis,
and the severity of kidney injury was observed. Similarly, no
correlation between the GFR and time lapse from treatment
completion was found.
The cumulative dose of nephrotoxic agents (IFA, CPA,
cisplatin and carboplatin) did not correlate with the severity
of kidney injury (Table 4).
There was no statistically significant difference in GFR
between the subgroup of children treated with radiotherapy
e.g. to the lumbar spine and those who did not receive
radiotherapy.
Children with CKD (GFR < 60 ml/min/1.73 m2) showed
significantly higher levels of CYS C (1500.21 vs
992.64 mg/L) and B2MG (2.06 vs 1.23 mg/L), as compared
to the remaining subjects. NGAL levels were comparable in
both subgroups (18.91 vs. 18.94 ng/ml) (Table 5).
A statistically significant negative correlation between the
eGFR estimated by Schwartz formula and CYS C levels
(p < 0.003) was shown across the entire study group. The cor-
relation between the eGFR estimated by the new Schwartz
formula and CYS C (p < 0.0001) results from the equation
itself. Furthermore, a correlation between the eGFR estimated
using the new Schwartz formula and B2MG was shown
(p < 0.02) (Fig. 1). Conversely, there was no correlation be-
tween eGFR and NGAL (p = 0.6) (Fig. 2).
Additionally, a strong positive correlation between serum
CYS C level and B2MG (p < 0.001) was observed. However,
no associations between CYS C and NGAL (p = 0.8) or
B2MG and NGALwere found (p = 0.4).
Thirteen children (34 %) developed drug-induced
tubulopathy: decreased tubular reabsorption of phosphate
(TRP and TmP/GFR). It manifested as hypophosphatemia
and hyperphosphatur ia . Hypophosphatemia and
hypomagnesaemia were found in 36 and 13 % of study sub-
jects, respectively. Serum levels of calcium, sodium and po-
tassium in all subjects were within the normal range. All urine
samples tested negative for the presence of glucose and pro-
tein. Mild metabolic acidosis manifesting as slightly de-
creased blood pH and BE (acid–base equilibrium) was shown
Table 3 Distribution of patients considering the degree of kidney
damage
eGFR
eGFR >90 ml/min/1.73 m2 eGFR 60–90 ml/min/1.73 m2
No nephrotoxicity Stage 2 of nephrotoxicity
10 pts (26.5 %) 22 pts (58 %)
eGFR estimated glomerular filtration rate
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in 3 (1 %) patients (Table 6). Microalbuminuria was present in
five children.
CYS C and B2MG levels also showed a strong positive
correlation with TRP and TmP/GFR (p < 0.001). There was no
such correlation between NGAL and TRP (p = 0.7) or NGAL
and TmP/GFR (p = 0.762).
Ultrasound image of kidneys appeared normal in all chil-
dren. Except for one 22-year-old patient with average blood
pressure of 137/87 mm/Hg, the blood pressure measurements
were consistently normal across the entire group.
Discussion
Currently, as the 5-year survival in children with different
malignancies has reached almost 70 %, oncologists aim at
offering cancer survivors the best possible quality of life.
According to published data, 40 % of cancer survivors devel-
op chronic conditions [15]. Brain tumour survivors are the
most severely affected with late effects of cancer treatment
[16]. The most common sequelae include endocrine dysfunc-
tion, cardiotoxicity, neurotoxicity and nephrotoxicity.
According to some authors, chronic nephrotoxicity affects
30–70 % of children after previous antineoplastic therapy
[6]. Since CKD leads to end-stage renal failure in many cases,
its early diagnosis and appropriate treatment may have a sig-
nificant impact on its course. However, potential preventive
and therapeutic interventions are often delayed. Hence,
prompt diagnosis during the prodromal stage is necessary,
followed by the long-term observation.
Commonly used nephrotoxicity markers such as serum cre-
atinine level have many limitations. Serum creatinine level
depends on numerous confounding factors: muscle mass, sex,
age, diet, muscle metabolism, body hydration and applied med-
ications. Serum creatinine level is elevated as a result of dam-
age to at least 50 % of kidney parenchyma. Moreover, elevated
creatinine level is not specific for tubular damage [11].
GFR
The eGFR is an estimator of functional nephron count used in
clinical practice. It constitutes a basis for CKD staging [17].
Fitness level conditions endogenous creatinine and estimation
of GFR. Furthermore, the determination of GFR using inulin
(the gold standard for determining GFR) is associated with
many obstacles, such as the need for repeated blood sampling,
which may be troublesome particularly in paediatric popula-
tion. Taking into consideration these reservations, the research
for better parameters of GFR is ongoing. Mathematical equa-
tions involving additional parameters may increase diagnostic
sensitivity of GFR in an individual patient. The National
Kidney Foundation (NKF) recommends the Schwartz formula
for estimating GFR in children (https://www.kidney.org/
content/creatinine-based-%E2%80%9Cbedside-schwartz%
E2%80%9D-equation-2009). In 2009, Schwartz published a
new, revised equation to estimate GFR in children with CKD.
The new formula is based on the serum concentration of
creatinine, CYS C and uric nitrogen [12]. According to
some authors, the simultaneous use of at least two methods
(GFR estimated based on serum creatinine and CYS C levels)
offers more reliable results [18].
As a part of our study, renal function in each patient was
estimated using both Schwartz formula and revised Schwartz
formula. The difference between the mean GFR estimated by
Table 4 Correlation between eGFR and the cumulative dose of nephrotoxic agents
Drug cumulative dose Cisplatin Carboplatin Ifosfamide Cyclophosfamide
<450 mg/m2 >450 mg/m2 <1100 mg/m2 >1100 mg/m2 0 g/m2 9–36 g/m2 0 g/m2
Number of patients 18 20 16 22 20 18 25
eGFR Shwartz 66 60 57 65 66 59 60
p 0.15 0.14 0.08 0.09 – 0.11 –
eGFR estimated glomerular filtration rate
Table 5 Serum Cys C, NGAL and B2MG among patients with and without nephrotoxicity
Serum CysC (ng/ml) Serum NGAL (ng/ml) Serum B2MG (mg/l)
eGFR new Shwartz >60 ml/min/1.73 m2 992.64 (554.55–1642.9) 18.91 (8–44.7) 1.235 (0.75–2.45)
eGFR new Shwartz 30–60 ml/min/1.73 m2 1500.21 (728.36–2906.1) 18.94 (9.2–51.7) 2.068 (1.25–5.93)
p <0.001 0.6 <0.01
Cys C cystatin C, NGAL neutrophil gelatinase-associated lipocalin, B2MG beta-2 microglobulin, eGFR estimated glomerular filtration rate
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Schwartz formula (76 ml/min/1.73 m2) and GFR estimated
revised Schwartz formula (63 ml/min/1.73 m2) was statistical-
ly significant (p < 0.0001).
In this study, the laboratory signs of subclinical nephrotox-
icity (eGFR of 90–60 ml/min/1.73 m2) were observed in
57.8 % of patients, which corresponds to the findings by other
authors [19]. In our patient cohort, 15.7 % of cancer survivors
had eGFR of 60–30ml/min/1.73 m2 (including one individual
with eGFR of 34 ml/min/1.73 m2). Skinner et al. found eGFR
<60 ml/min/1.72 m2 in 13 % of their 25-person study group
with malignant sarcoma treated with IFA before the end of 10-
year follow-up [20]. Similarly, in a group of 63 patients treated
with cisplatin, 11 % of subjects had decreased GFR at the end
of the 10-year follow-up [7]. Oberlin et al. found decreased
GFR <60 ml/min/1.73 m2 in 21 % of patients with GFR being
as low as 50.1 ml/min/1.73 m2 in a single case. Their study
group included children treated with IFA for soft tissue sarco-
mas and bone sarcomas [6]. In the study by Zubowska et al.,
20 % of childhood cancer survivors developed CKD
(GFR < 60 ml/min/1.72 m2) [19]. Most studies were carried
out on mixed case groups including only a few brain tumour
survivors [19, 20]. We have not found any studies focusing on
late nephrotoxicity in patient samples consisting only of brain
tumour survivors.
We did not find an association between the age at diagnosis
and GFR in contrast to other authors who report correlations
between CKD and patient age. Skinner [21] showed more
severe proximal tubular toxicity in younger children treated
with IFA, as compared to older children. However, the same
author later found older age at treatment to be a risk factor for
cisplatin nephrotoxicity [7]. There are also other papers em-
phasizing that patients younger than 5 years are more likely to
develop CKD [21–23]. Perhaps the lack of correlation of GFR
with age in our work results from the fact that an average age
of children was 9.5 years (consistent with epidemiological
data regarding the age of the incidence of malignant CNS
tumours), and there were only two children under 5 years of
age in the studied group.
The fact that our study failed to show relationship between
specific factors such as age and total dose of administered
drugs could also be related to the modest sample size.
We did not observe an association between the time in-
terval from treatment completion and GFR. Similarly,
Zubowska et al. did not observe the association between
the follow-up time and nephropathy in a group observed
for the mean period of 4.6 years [19]. Furthermore, other
authors who carried out their studies at 10 years following
chemotherapy completion did not observe kidney function
deterioration with time [20]. However, Oberlin in her study
on 138 patients who had completed chemotherapy at least
5 years earlier found a longer follow-up period to be an
independent risk factor for abnormal GFR [6]. On the other
hand, there are papers reporting spontaneous recovery of
renal function after chemotherapy [25, 26].
Many authors indicate an association between kidney dam-
age and cumulative dose of chemotherapeutics. It is true for
both such platinum derivatives as carboplatin, cisplatin [25,
26] and IFA [6, 24].
We did not confirm an association between the total dose of
chemotherapeutics (cisplatin, carboplatin, IFA and CPA) and
GFR, which might potentially be attributed to the fact that all
children in our study group received chemotherapy in line
with approved treatment protocols involving simultaneous
use of IFA and/or CPA as well as cisplatin and/or carboplatin.
Multidrug chemotherapy may constitute a confounding factor.
All quoted papers assessed nephrotoxicity after monotherapy.
Other authors reported a significant effect of IFA on the kid-
ney function when a cumulative dose of the drug exceeded
60 g/m2. Children in our study group did not receive such a
high total dose of IFA. In the literature, there is no conclusive
data on the toxic dose of cisplatin. Skinner showed toxic effect
of a daily dose of cisplatin exceeding 40 mg/m2. There is the
lack of data on toxic total doses of carboplatin.
There was no statistically significant difference in GFR
between the subgroup of children treated with craniospinal
radiation therapy and those who did not receive radiotherapy.
In Zubowska paper, the higher frequency of nephrotoxicity
Fig. 1 Correlation between eGFR C and B2 microglobulin (p < 0.02)
Fig. 2 Correlation between eGFR C and NGAL (p = 0.6)
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was observed among the children after abdominal radiothera-
py [19].
Markers of kidney injury
There are many studies assessing new markers of early kidney
damage, immediately after activation of a damaging factor
[10]. Very few biomarkers exist for monitoring CKD.
Neutrophil gelatinase-associated lipocalin (NGAL) is a
protein secreted to urine by the cells of the thick ascending
limb of loop of Henle and a connecting tubule [27]. Based on
the available published data NGAL is thought to be a novel,
sensitive and specific early marker of acute kidney injury
(AKI) [11]: in ischemic acute kidney injury [28, 29], in a
septic shock [30], in contrast-induced nephropathy [31].
However, the role of measurement of NGAL in CKD is still
unclear. Several recent studies have showed increased serum
NGAL levels in cases with CKD [32–34]. Mitsnefes et al.
showed that serum NGAL significantly correlated with
cystatin C and both NGAL and cystatin C significantly corre-
lated with eGFR in children with CKD stages 2–4 [35]. In our
study, no significant association between plasma NGAL
levels and eGFR was found, and NGAL levels in children
with kidney injury were comparable to those in children with
normal eGFR. In line with Forest Fire Theory [35], we con-
sider NGAL to be a marker of an early as well as AKI. An
initial elevation of NGAL level directly after the exposure to
an insulting agent (Bburning trees^) is followed by its decrease
to the values comparable with those of healthy individuals
(Bburnt out trees^). Our findings correspond to those of
Nikolas in a sample of 635 patients: NGAL levels in patients
with CKD and those with normal kidney function were com-
parable [36]. Plasma NGALmeasurements may be influenced
by a number of coexisting variables such as chronic hyperten-
sion [37], systemic infection [38] and neoplasms [39]. Recent
studies have showed that in the primary brain neoplasms,
NGAL is over-expressed in tumours, which correlates with
elevated serum and urine NGAL [40, 41]. Thus, it seems that
the concentration of serum NGAL in children with cancer can
be caused by many factors and not only resulting from kidney
damage.
CYS C undergoes glomerular filtration and a complete re-
absorption in proximal tubules. However, it is not involved in
tubular secretion. The stability of the molecule of CYS C and
the fact that its concentration in blood depends only on the
glomerular filtration rate affects its high diagnostic efficiency
[42]. CYS C has been studied intensively as a marker of kid-
ney function in adults and in children. A number of cross-
sectional studies have been published showing that serum
CYS C concentration is more sensitive and correlate better
to GFR than creatinine [43, 44]. Many reports emphasize that
serum cystatin C is a better indicator of GFR than serum
creatinine concentration both in patients with chronic kidney
damage [45] including chemotherapy [46]) and in patients
with acute kidney injury: in papers by Liang [47] and
Krawczewski [48]. Cys C level increased as early as 12 h
following the exposure to a nephrotoxic agent and preceded
the elevation of creatinine level by 1–2 days. Similarly, we
showed a statistically significant negative correlation between
the eGFR estimated by Schwartz formula and CYS C levels
(p < 0.003) across the entire study group. Children with CKD
(GFR < 60 ml/min/1.73 m2) had significantly higher levels of
CYS C as compared to the remaining subjects (p = 0.001).
Beta-2 microglobulin (B2MG) is a subunit of the major
histocompatibility class I molecule produced by all nucleated
cells [49]. Its small size (11.8 kDa) allows beta-2-M to pass
through the glomerular membrane, but it is almost completely
reabsorbed in the proximal tubules. Serum beta-2-M levels are
elevated in diseases associated with the increased cell turn-
over. This assay offers improved diagnostic sensitivity for
the detection of altered GFR as compared to serum creatinine
[50]. B2MG level is also elevated in several benign conditions
such as chronic inflammation, liver disease, some acute viral
infections and a number of malignancies, especially
haematologic malignancies associated with the B cell lineage
[51]. Many studies showed a very strong association between
plasma B2MG levels and GFR [52]. However, there are few
reports evaluating the B2MG in children after chemotherapy.
In our study, we observed a statistically significant negative
correlation between GFR and B2MG levels (p < 0.02).
Additionally, we observed a strong positive correlation be-
tween serum CYS C level and B2MG (p < 0.001). However,
Table 6 Concentration of Mg, P,
Ca and TRP, TmP/GFR in
patients
Patients
With tubulopathy Without tubulopathy
Serum P (mmol/l) 1.17 (min: 0.96–max: 1.18) 1.28 (min: 1.0–max: 1.49)
Serum Mg (mmol/l) 0.86 (min: 0.54–max: 0.97) 0.79 (min: 0.58–max: 1.1)
Serum Ca (mmol/l) 2.55 (min:2.53–max: 2.67) 2.52 (min: 2.34–max: 2.64)
TRP (%) Median:76.2 (min: 64–max: 84.9) Median: 89.2 (min:85.1–max: 97)
TmP/GFR Median: 0.83 (min: 0.55–max: 0.98) Median: 1.09 (min: 0.88–max: 1.67)
TRP renal reabsorption of phosphate, TmP/GFR renal tubular threshold for phosphate, GFR glomerular filtration
rate
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we did not observe an association between CYS C and NGAL
(p = 0.8) or B2MG and NGAL (p = 0.4).
Tubulopathy
Fanconi syndrome is characterized by a global transport defect
in the proximal tubules of the kidney. The spectrum of tubular
dysfunction varies in different patients, ranging from a general-
ized proximal tubulopathy to partial reabsorption defects in
phosphorus, calcium, glucose, amino acids and bicarbonate.
The mechanism by which IFA induces Fanconi syndrome has
not been identified [8]. Distant effects of IFA tubulopathy in
children may be growth retardation [24] and the bone disease
rickets [53]. CPA, an isomer of IFA, displays only side effects in
the form of haemorrhagic cystitis but not other nephrotoxicities.
In our study, 36 % of children presented with
hypophosphatemia, which corresponds with the remaining
signs of tubulopathy. Decreased fractional TRP (TRP < 85 %)
and the decreased ratio of tubular maximum reabsorption of
phosphate to GFR (TmP/GFR < 1.15) were found in 34 % of
patients. The patients with hypophosphatemia also showed de-
creased tubular reabsorption and TmP/GFR. All subjects had
normal serum and urine sodium, potassium and calcium levels.
Among all patients, the osmolality of urine and plasma was
normal. For this reason, we did not measure tubular handling
of sodium, calcium and potassium. All urine samples tested
were negative for the presence of glucose and protein. Three
patients were found to have mild metabolic acidosis, which did
not require intervention. Five children had microalbuminuria
(including one patient with other symptoms of tubulopathy). In
summary, 1/3 of children presented partial Fanconi syndrome,
which c l in i ca l ly mani fes ted i t se l f main ly wi th
hypophosphatemia and hyperphosphaturia. These findings
confirm results obtained by other authors, who observed per-
sistent dysfunction of renal proximal tubule cells in 5–10 % of
children treated only with IFA [6, 23] and in 30–40 % of chil-
dren treated with IFA and concurrent administration of cis or
carboplatinum [24]. Patients included in these studies were
mainly children after treatment of bone and soft tissue sarco-
mas, neuroblastoma and Wilms’ tumour. We have not found
any studies focusing on tubular function assessment in patients
after brain tumour therapy in children.
None of our patients experienced hemorrhagic cystitis
caused by the CPA, which was probably associated with pro-
phylactic administration of the uroprotectant mesna and inten-
sive hydration during and after chemotherapy.
Conlusions
Summing up, children treated for CNS tumours often develop
drug-induced chronic renal disease, involving the glomeruli
and/or renal tubules. The strength of our work is the fact that it
was carried out on a homogeneous research group. The down-
side is a small size of the group, due to the fact it was con-
ducted in a single centre and low survival rate of patients with
the disease (the highest mortality rate of all cancers in chil-
dren). Further study should be performed in larger group of
patients, in multicenter studies. Longer time of follow-up is
needed to constitute conclusions assessing the changes in the
kidney in the course of time. Our data suggests the confirma-
tion of the hypothesis that CYS C and B2MG can be used as
markers of chronic kidney injury after chemotherapy in chil-
dren, which is probably not true for NGAL. It also seems that
none of these markers meets the criterion of universal indica-
tor of kidney damage and it is necessary to develop a diagnos-
tic panel to detect kidney injury in a preclinical phase.
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